Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4832812 | 0.89 | KCNH2 (0.38) | KCNH2HDAC1HTR2ADRD2HTR2C | |
| SCHEMBL4833317 | 0.86 | ALDH1A1 (0.47) | KCNH2HDAC1HTR2ADRD2HTR2C | |
| SCHEMBL4839375 | 0.85 | NPSR1 (0.48) | KCNH2HDAC1HTR2ADRD2HTR2C | |
| SCHEMBL4837490 | 0.85 | NPSR1 (0.48) | KCNH2HDAC1HTR2ADRD2HTR2C | |
| SCHEMBL4838414 | 0.85 | HTR2A (0.42) | KCNH2HDAC1HTR2ADRD2HTR2C | |
| SCHEMBL4839710 | 0.79 | HSD11B1 (0.38) | KCNH2HDAC1 | |
| SCHEMBL4838758 | 0.79 | MCHR1 (0.46) | DRD2DRD3 | |
| SCHEMBL4839706 | 0.77 | KCNH2 (0.35) | KCNH2HDAC1HTR2ADRD2HTR2C | |
| SCHEMBL4839787 | 0.77 | HTR2A (0.47) | HTR2ADRD2DRD3 | |
| SCHEMBL4839076 | 0.76 | DRD2 (0.51) | HDAC1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384957-B2 | 3,4-dihydro-1H-isoquinolin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2008-06-10 | — | — | US | claimed |
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2005-03-31 | — | — | US | claimed |
| US-7384957-B2 | 3,4-dihydro-1H-isoquinolin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2008-06-10 | — | — | US | disclosed |
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | KCNJ2, KCNK2, KCNJ11 | KCNH2 24/4885HDAC1 2287/4885HTR2A 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.